智通财经网·2025-09-26 10:55Core Viewpoint - Fosun Pharma is planning to transfer 100% equity of Shanghai Clone to enhance focus on core business and improve asset operation efficiency [1][2] Group 1: Transaction Structure - Fosun Pharma's subsidiary, Fosun Pharma Industry, will establish a special fund with a total planned fundraising of RMB 547 million, with contributions from various parties [1] - The fund will have Fosun Pharma Industry holding 9.98%, Hongyi Tianjin holding 0.18%, and Zhonghui Life holding 89.84% of the fund's assets [1] - The investment will be accounted for as other non-current financial assets at fair value after the fund is established [1] Group 2: Asset Transfer Details - Following the establishment of the special fund, Fosun Pharma Industry will transfer its 100% equity in Shanghai Clone for a total consideration not exceeding RMB 1.256 billion [2] - The main asset of Shanghai Clone includes state-owned land use rights and property ownership located at 1289 Yishan Road, Xuhui District, Shanghai, covering an area of 19,944 square meters with a building area of 45,238.55 square meters [2] - After the transfer, the group will no longer hold equity in Shanghai Clone but will continue to lease part of the property for operations, with Shanghai Fushun providing asset management services [2]